• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Friday, September 22, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

MD Anderson announces strategic collaboration with Denali Therapeutics to research and develop targeted therapies for neurodegenerative diseases

Bioengineer by Bioengineer
February 20, 2020
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: MD Anderson Cancer Center


HOUSTON — The University of Texas MD Anderson Cancer Center today announced a strategic research collaboration with Denali Therapeutics Inc. to develop novel therapies for Alzheimer’s and other neurodegenerative diseases. Through this agreement, Denali will collaborate with researchers in the Neurodegeneration Consortium (NDC) at MD Anderson to investigate four therapeutic targets, with the goal of advancing novel small-molecule product candidates into clinical testing.

Neurodegenerative diseases, which affect millions of Americans, comprise a range of indications marked by deterioration of neurons in the human brain, explained Jim Ray, Ph.D., director of the NDC.

“Our team at the Neurodegeneration Consortium is committed to advancing novel therapies that will translate into effective treatments for patients suffering from a variety of neurodegenerative diseases,” said Ray. “We at MD Anderson are pleased to work with Denali to investigate new therapeutic targets for these indications, with the goal of answering significant unmet medical needs.”

The NDC is a multi-institutional initiative launched to better understand the biology of neurodegenerative diseases and translate that knowledge into effective therapeutics interventions. Established in 2012 by an inaugural $25 million gift from the Robert A. and Renee E. Belfer Family Foundation, the NDC brings researchers from the Massachusetts Institute of Technology and the Icahn School of Medicine at Mount Sinai together with drug discovery and development experts from MD Anderson’s Therapeutics Discovery division.

The Therapeutics Discovery division is a drug discovery and development engine created within MD Anderson to bring impactful new therapies to patients quickly, safely and effectively. The team works closely with MD Anderson clinicians and researchers to develop novel small molecules, biologics and cell-based therapies, driven by insight from patients.

“Within Therapeutics Discovery, we are motivated to bring new therapies to the patients who need them,” said Ray. “Collaborations such as this are critical in helping us to realize our mission, and we look forward to working toward future benefit for patients with Alzheimer’s and other neurodegenerative diseases.”

###

About MD Anderson

The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 50 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 15 times in the last 18 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).

Media Contact
Clayton R. Boldt, Ph.D.
[email protected]
713-792-9518

Tags: cancerMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Sven Davisson to serve as Treasurer of AIRI

Louisiana Cancer Research Center Associate Director of Administration Sven Davisson named Treasurer of Association of Independent Research Institutes

September 22, 2023
Immune Cells

Australian research leads to clinical trial for rare women’s cancers

September 22, 2023

Cancer Prevention and Research Institute of Texas awards $2 million grant to SMU

September 21, 2023

Rewiring tumor mitochondria enhances the immune system’s ability to recognize and fight cancer

September 21, 2023
Please login to join discussion

POPULAR NEWS

  • blank

    Microbe Computers

    58 shares
    Share 23 Tweet 15
  • University of South Florida scientist: Barnacles may help reveal location of lost Malaysia Airlines flight MH370

    46 shares
    Share 18 Tweet 12
  • Lithuanian invention at the forefront of solar technology breakthrough

    41 shares
    Share 16 Tweet 10
  • A pioneering study from Politecnico di Milano sheds light on one of the still poorly understood aspects of cancer

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

UC San Diego Health named national leader in delivering high-quality patient care

Editorial addresses clinician burnout with unifying systems medicine model

Louisiana Cancer Research Center Associate Director of Administration Sven Davisson named Treasurer of Association of Independent Research Institutes

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 57 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In